If you have patients diagnosed with GIST, you may want to consider referring them to the intrigue study.
The intrigue study is a Phase 3 clinical research study to assess efficacy and safety of DCC-2618 compared to sunitinib in patients with advanced GIST who have received prior treatment with imatinib.
Key study eligibility criteria include:
- At least 18 years of age
- Histologic diagnosis of GIST (archival tissue sample or new biopsy required)
- Disease progression on imatinib or documented intolerance to imatinib
- ECOG PS of ≤ 2
Approximately 358 patients will be randomized 1:1 to receive either DCC-2618 (150 mg QD) or sunintinib (50 mg QD) in repeating 42-day treatment cycles. Patients will be eligible to receive DCC-2618 or sunitinib for up to 2 years. Study visits will be required during each cycle.
Please consider referring any potentially eligible patients for further evaluation.